Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:European_Medicines_Agency 2002 |
| gptkbp:ATCCode |
A16AX06
|
| gptkbp:CASNumber |
72599-27-0
|
| gptkbp:genericName |
gptkb:miglustat
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zavesca
|
| gptkbp:indication |
treatment of mild to moderate type 1 Gaucher disease in adults for whom enzyme replacement therapy is unsuitable
treatment of progressive neurological manifestations in Niemann-Pick type C disease |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Actelion_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
glucosylceramide synthase inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
tremor weight loss |
| gptkbp:usedFor |
gptkb:Niemann-Pick_disease_type_C
gptkb:Gaucher_disease_type_1 |
| gptkbp:bfsParent |
gptkb:miglustat_(for_Type_C)
|
| gptkbp:bfsLayer |
6
|